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Our study is the first report of exceptional
Mycobacterium bovis strains that have some characteris-
tics of M. tuberculosis. The strains were isolated from 8
patients living in Kazakhstan. While molecular markers
were typical for M. bovis, growth characteristics and bio-
chemical test results were intermediate between M. bovis
and M. tuberculosis. 
M
ycobacterium bovis causes tuberculosis (TB) mainly
in cattle but has a broad host range and causes dis-
ease similar to that caused by M. tuberculosis in humans
(1). It belongs to the M. tuberculosis complex (MTBC)
that comprises the closely related human pathogens M.
tuberculosis and  M. africanum (2). Identification of M.
bovis traditionally has been based on clear-cut differences
in phenotypic characteristics and biochemical properties
when compared to the other members of the MTBC (1,2).
M. bovis shows a dysgonic colony shape on Lowenstein-
Jensen medium, is negative for niacin accumulation and
nitrate reduction, is susceptible to thiophene-2-carboxylic
acid hydrazide (TCH), and shows microaerophilic growth
on Lebek medium (1–3). Afurther criterion used for differ-
entiation is the intrinsic resistance to pyrazinamide, which
is found in most M. bovis isolates (1–3). In contrast, M.
tuberculosis shows eugonic growth, is positive for niacin
accumulation and nitrate reduction, is resistant to TCH,
shows aerophilic growth on Lebek medium, and is usually
not monoresistant to pyrazinamide (2,3).
More recently, several molecular methods have been
developed that provide clear criteria for the identification
of M. bovis. These comprise a variety of polymerase chain
reaction (PCR) methods, e.g., based on DNA sequence
variations in the direct repeat region of MTBC complex
strains (spoligotyping [4]) or on single nucleotide poly-
morphisms (SNPs) in either the oxyR gene (5) or the gyrB
gene (6). Furthermore, MTBC isolates can be differentiat-
ed by large sequence polymorphisms or regions of differ-
ence (RD), and according to their distribution in the
genome, a new phylogenetic scenario for the different
species of the MTBC has been suggested (7–9). The pres-
ence or absence of particular deletions has been proposed
as being discriminative, e.g., lack of TdB1 for M. tubercu-
losis or lack of RD12 for M. bovis.
In routine diagnostics, the combination of phenotypic
characteristics and biochemical features is sufficient to dif-
ferentiate clinical M. bovis isolates, and in general, the
results obtained are unambiguous. However, here we
describe the characteristics of 8 strains of the MTBC that
showed an unusual combination of phenotypic and bio-
chemical attributes of both M. bovis and M. tuberculosis.
Molecular analyses confirmed the strains as M. bovis,
which in part have phenotypic and biochemical properties
of M. tuberculosis. 
The Study
During a previous investigation of 179 drug-resistant
isolates from Kazakhstan (10), we determined the presence
of 8 strains showing monoresistance to pyrazinamide.
Kazakhstan is the largest of the central Asian republics and
is divided regionally into 14 oblasts. The investigation was
performed as part of a nationwide drug resistance survey
conducted by the national TB program of Kazakhstan with
assistance from the World Health Organization/
International Union against Tuberculosis and Lung
Disease Global Project in 2001. The subset of this survey
investigated here (n = 158) represents 100% of strains
resistant to isoniazid, rifampin, ethambutol, or strepto-
mycin isolated in 9 of the 14 Kazakhstan oblasts during the
study period; 21 samples had fungal contamination or
showed no growth (10). All strains were isolated from spu-
tum samples. 
To further clarify if these strains were monoresistant M.
tuberculosis or M. bovis isolates intrinsically resistant to
pyrazinamide, we performed several routine diagnostic
tests traditionally used for species differentiation (6). All
strains showed eugonic growth characteristics on
Lowenstein-Jensen slants and on bromcresol purple medi-
um (Figure), which in general is typical for M. tuberculosis.
However, on bromcresol purple medium, classic M. tuber-
culosis isolates induce a pH-dependent change of color
from blue to yellow, which was not observed in these cases
(Figure). Furthermore, all 8 isolates were positive for niacin
accumulation, negative for nitrate reduction, susceptible to
TCH, and showed aerophilic growth on Lebek medium.
Considering all results, the 8 strains showed a combination
of test results that did not allow a clear differentiation as M.
bovis or as M. tuberculosis (Table 1). Such a combination
of test results would apply best to M. africanum, a species
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(3). However, this species was probably was not isolated
because M. africanum strains are usually not monoresis-
tant to pyrazinamide (3). 
Therefore, we investigated all strains with several
molecular techniques previously used for differentiation
within the MTBC (Table 2). They all had identical spolig-
otype patterns (hexcode 6B-57-5F-7F-FF-60, performed
according to the methods of Kamerbeek et al. [4]), that
lacked spacers 39–43 and identical IS6110 DNA finger-
print patterns with 2 IS6110 copies (data not shown, per-
formed according to the methods of van Embden et al.
[11]). All isolates carried the M. bovis–specific polymor-
phism in the oxyR gene (5), and none of them had the M.
bovis BCG– specific deletion in the RD1 region (12). PCR
analysis of other RDs (RD3, RD4, RD5, RD9, RD10,
RD12, TbD1, and IS1541) showed results typical for M.
bovis when compared with the RD signatures of the
American Type Culture Collection strains of M. tuberculo-
sis, M. africanum, and M. bovis (Table 2) and with previ-
ously published data (7,8). The intrinsic resistance to
pyrazinamide was confirmed by DNA sequence analysis
as all strains carried the M. bovis–specific single point
mutation at nucleotide position 169 of the pncA gene.
Seven of the 8 strains were isolated from 30- to 55-
year-old men, and 1 strain was from a 72-year-old woman.
All but 1 patient had a history of previous antituberculosis
treatment, but none of the strains showed any further
resistance (data not shown). The patients originated from
the oblast of Kostanajskaya in north Kazakhstan. Among
all patients, no direct epidemiologic links could be estab-
lished. However, 3 of the patients lived in the city of
Kostanaj, while 5 came from rural areas. Before 1950, the
Kazakh Steppe was a broad, continuous belt of grassland
that stretched from the Ural River to the Altai foothills,
covering large parts of Kostanajskaya; after the 1950s, the
region was used extensively for agriculture. Information
on contact with animals is not available, since cattle herds
are only kept privately.
Conclusions
We describe 8 strains of M. bovis with exceptional phe-
notypic characteristics that are intermediate between M.
tuberculosis and M. bovis. This fact initially complicated a
clear species differentiation; however, the battery of
molecular tests performed clearly confirmed all strains as
M. bovis. These tests included the presence of characteris-
tic single nucleotide polymorphisms as well as an RD pro-
file that is typical for the M. bovis lineage of the MTBC
(6,7). To our knowledge, this is the first report describing
M. bovis isolates with phenotypic characteristics and bio-
chemical properties of M. tuberculosis. In our previous
investigation of 176 M. bovis strains from Germany, all
strains had phenotypic characteristics typical of M. bovis,
and no strains similar to the isolates from Kazakhstan
could be identified (13). The same result applies for the
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Figure. Growth morphology on bromcresol purple medium of
Mycobacterium bovis (A), M. tuberculosis (C), and 1 of the strains
analyzed (B).spoligotype patterns, as none of the strains in our database
had an identical spoligotype pattern (data not shown). A
further comparison with the international M. bovis spolig-
otype database (available from http://www.mbovis.org/
spoligodatabase) identified 1 strain isolated in Argentina
with an identical spoligotype pattern; however, no further
information about his strain is available. 
Whether the 8 strains analyzed represent strains of an
ancestral phylogenetic lineage of M. bovis that might have
been conserved because of the geographic isolation of that
region of Kazakhstan or whether they gained their special
characteristics by new mutations is a question that cannot
be answered by the data obtained in this study. All strains
have been isolated from humans. We cannot say if we have
found an exceptional outbreak of a particular M. bovis
strain or if the patients were infected directly by wildlife,
livestock, or food, and the disease developed by chance
during the study. However, an overall percentage of ≈5%
of all resistant strains investigated in this study indicates
that these isolates may be important in Kazakhstan. This
also poses the question of whether these strains might
become more virulent in humans if they acquired pheno-
typic/biochemical characteristics usually observed exclu-
sively in M. tuberculosis. However, to address this
question more precisely, longitudinal studies on the popu-
lation structure of MTBC isolates in Kazakhstan obtained
from humans and animals, in combination with experi-
ments in virulence model systems, will be necessary. In
any case, these strains represent ideal model organisms for
analyzing the nature of the biologic differences observed
between M. bovis and M. tuberculosis. To ensure a clear
differentiation from other M. bovis strains, we suggest the
name  M. bovis subtype “Almaty” for this genotype.
Almaty is the former capital and largest city of
Kazakhstan.
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